2.66

2.56% -0.07

After Hours: 2.66

Turnstone Biologics Corp (TSBX)

Overview News Price History Financials Discussions Forecast

Turnstone Biologics Corp stock is currently priced at $2.66, with a 24-hour trading volume of 108.94K. It has seen a -2.56% decreased in the last 24 hours and a -1.12% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $2.74 pivot point. If it approaches the $2.57 support level, significant changes may occur.

Previous Close:

$2.73

Open:

$2.73

24h Volume:

108.94K

Market Cap:

$61.52M

Revenue:

$81.89M

Net Income/Loss:

$-55.20M

P/E Ratio:

EPS:

Net Cash Flow:

$-67.40M

1W Performance:

-12.79%

1M Performance:

-1.12%

6M Performance:

-20.83%

1Y Performance:

+0.00%

1D Range:

$2.61

$2.79

52W Range:

$1.625

$9.575

Turnstone Biologics Corp Stock (TSBX) Company Profile

Name

Turnstone Biologics Corp

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

347-897-5988

Address

9310 Athena Circle, Suite 300, LA Jolla

Employee

108

Twitter

Next Earnings Date

Latest SEC Filings

TSBX's Discussions on Twitter

Turnstone Biologics Corp Stock (TSBX) Latest News

Turnstone Biologics reports Q1 EPS (85c), two estimates (77c) - TipRanks.com - TipRanks

TipRanks

Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights - ForexTV.com

ForexTV.com

Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights ... - wallstreet:online

wallstreet:online

Turnstone Biologics announces board member resignation - Investing.com ZA - Investing.com South Africa

Investing.com South Africa

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

GlobeNewswire Inc.

Turnstone Biologics to Participate in Upcoming Investor Conferences

GlobeNewswire Inc.

Turnstone Biologics Corp Stock (TSBX) Financials Data

Turnstone Biologics Corp (TSBX) Revenue 2024

TSBX reported a revenue (TTM) of $81.89 million for the quarter ending March 31, 2023.

Turnstone Biologics Corp (TSBX) Net Income 2024

TSBX net income (TTM) was -$55.20 million for the quarter ending December 31, 2023, a -79.02% decrease year-over-year.

Turnstone Biologics Corp (TSBX) Cash Flow 2024

TSBX recorded a free cash flow (TTM) of -$67.40 million for the quarter ending December 31, 2023, a +11.58% increase year-over-year.

Turnstone Biologics Corp (TSBX) Earnings per Share 2024

TSBX earnings per share (TTM) was -$2.6959 for the quarter ending December 31, 2023, a -94.01% decline year-over-year.

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.